The FDA has approved the first rapid-acting biosimilar insulin product for glycemic control in people with diabetes. Merilog ...

Danish drugmaker Novo Nordisk reported fourth quarter and full year 2024 earnings Wednesday, beating Wall Street's ...

NVO's fourth-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially ...

Many who would benefit from the drug find the idea of a weekly injection a turnoff. Novo Nordisk's recent announcement that Wegovy in a tablet proved as effective as the shots could open the ...

Two U.S. senators wrote a letter to the Food and Drug Administration on Friday expressing concerns about an upcoming Super ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...